SPRO · Spero Therapeutics, Inc.
Market Cap
$71.63M
Shares
58.23M
Volume · Oct 5
942.72K
Avg daily vol (3M)
1.19M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.16
Open$1.17
Day$1.15–1.20
52W close$1.11–2.98
Avg vol 30d712K
Short int976K · 1.7% float · 3.1d
Short vol47%
Last earningsAug 12, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Dec 5, 2026
Est · unconfirmed
· in 9 wks
filed Aug 12, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$47.00M
Trailing 12 months
Net income (TTM)
$7.38M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
12.8%
Trailing 12 months
P / E (TTM)
8.5
Trailing earnings · reciprocal yield 11.8%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.5%
Year over year · more shares
Price change (1Y)
-41.4%
Trailing year
Short interest
1.7%
Latest settlement · 3.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 12, 2026
Q2 FY26
TL;DR. Spero secured FDA approval of Utebzi (first oral carbapenem for cUTIs), in-licensed Phase 2-ready anti-CD40L antibody SP001 from Innovent, and closed a $105M non-dilutive royalty financing extending cash runway into 2H 2029. The company's net loss widened to $9.6M from $1.7M, with no Q2 revenue versus $14.2M a year ago as collaboration revenue was fully recognized in prior periods.
Bullish
- + FDA approved Utebzi, the first and only oral carbapenem for complicated UTIs, with GSK expected to make it available to U.S. patients by end of 2026.
- + Closed $105M non-dilutive, non-recourse royalty financing with HCRx, structured to retain 35% of future Utebzi proceeds after notes are repaid, extending cash runway into 2H 2029.
- + In-licensed SP001 (anti-CD40L mAb) from Innovent for up to ~$1.1B in contingent deal value, with a Phase 2 trial in IgG4-related disease planned to begin in 2Q 2027.
- + Appointed a new CMO (Dr. Deborah Zak) with 25+ years of immunology drug development experience to lead SP001 clinical strategy.
Bearish
- − Q2 revenue was zero versus $14.2M in Q2 2025, as collaboration revenue from Pfizer and GSK and all grant revenue were fully recognized in prior periods.
- − G&A expenses rose to $6.5M from $5.9M, driven by higher business development, legal, and consulting costs tied to the SP001 in-licensing transaction.
- − Cash and cash equivalents stood at only $50.8M at quarter-end, with the upcoming $35M upfront payment to Innovent due to fund SP001 development.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−45%
below
Price vs 50-day avg
−4%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
3%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−58%
trailing
YTD return
−50%
this year
Relative strength
−70%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+22% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.68% of float · ▼ -19.3% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
61 holders — near 3-yr high, broad support
Squeeze score
38
low risk · 0–100
Fundamentals
Revenue growth
+39%
Y/Y
EPS growth
+112%
Y/Y
Free cash flow
$-12.8M
Valuation
P/E 8.8
in line
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−45%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
3%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+22% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.68% of float · ▼ -19.3% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
61 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 3%
Range high $3
vs 200-day avg -45%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRO
this stock
Spero Therapeutics, Inc.
|
$71.63M | -50.2% | +39.2% | 8.8 | 1.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRO | -2.5% | -4.1% | -58.3% | -4.1% | -50.2% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -3.7% | -4.7% | -69.8% | -5.7% | -63.8% |